as well as the short follow-up period. Future studies will need to explore the pleiotropic and antiinflammatory effect of statins. PB1273|Recurrent Thrombosis Rescued by Fondaparinux in High-risk Sufferers: Case Series and Assessment of Literature PB1272|A Realist Evaluation on Therapeutic Elastic Compression Therapy Pathways for DVT- and CVD Individuals to Create Evidence-informed Improvement Approaches R.H. Schreurs1 1,two,Conclusions: This study offers a detailed insight into what requirements to become in spot to optimize ECS-therapy and to inform implementation tactics.M. Tanguay1; C. S uinMcGill University, Department of Medicine, Montreal, Canada; 2McGillUniversity, Division of Medicine, Division of Hematology, Montreal, Canada; M.A. Joore ; D. De Bruijn-Geraets ; Background: Thrombotic illness remedy alternatives are restricted when anticoagulation with dose escalation of low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) fail. Fondaparinux is usually a pure, synthetic pentasaccharide that consists of heparin’s essential 5 sugar chain that binds antithrombin to inactivate element Xa. There’s scarce data concerning fondaparinux’s use in recurrent thrombosis. Aims: To highlight fondaparinux’s possible role in anticoagulantrefractory thrombosis. Methods: Six patients received fondaparinux immediately after thrombosis progression in our center in between 2016 and 2021. Their clinical data was retrieved and analysed. Outcomes: Patient traits and evolution on therapy are included in table 1. Of these six individuals, two have been previously diagnosed having a high-risk thrombophilia (triple optimistic antiphospholipid syndrome (APS) and homozygous aspect V Leiden) and 4 had an underlying Bcl-2 Inhibitor manufacturer malignancy. Half on the individuals had been female, and their median age was 52 (variety 281). 4 had thrombosis recurrence on elevated LMWH weight-adjusted doses (mean raise of 27.five , variety 150 ) and two had thrombosis recurrence on therapeutic UFH. Whilst on LMWH or UFH: the APS patient FP Antagonist Compound developed a valvular thrombus with arterial microemboli, one patient had progressive upper extremity catheter-related deep vein thrombosis (DVT), yet another patient developed lower extremity DVT and pulmonary emboli and 3 other individuals skilled worsening reduce extremity DVTs. Heparin-induced thrombocytopenia was viewed as and ruled out in every single case. Hence, all individuals have been treated with fondaparinux for a duration ranging from 26 days to 16 months. All patients had a normal renal function. No progression of thrombus was observed in 100 of individuals. Reduction of valvular thrombusH. Ten Cate1,two,3; A.J. Ten Cate-Hoek1,2 Thrombosis Professional Centre Maastricht and Laboratory for Cardiovascular Study Institute Maastricht (CARIM), Maastricht, Clinical Thrombosis and Haemostasis, Maastricht, Netherlands;Netherlands; 3Department of Internal Medicine, Maastricht University Health-related Centre, Maastricht, Netherlands; 4Department of Clinical Epidemiology and Medical Technologies Assessment, Maastricht, Netherlands Background: Elastic compression stocking (ECS) therapy is properly established in clinical practice for patients with deep venous thrombosis (DVT) and chronic venous disease (CVD). Having said that, considerable variations exist for its implementation in clinical practice, which may possibly effect patient outcomes. We previously identified six improvement themes for optimization of ECS therapy working with the Functional Resonance Evaluation System (FRAM). Aims: This study aims to expand theoretical understanding employing a realist